InSync ICD Joins Contak For Dual Indication: 100,000 CRT Patients Eligible
This article was originally published in The Gray Sheet
Executive Summary
Medtronic expects FDA approval of the InSync ICD on June 26 will allow the company to control 60% of the 750,000-patient U.S. cardiac resynchronization therapy (CRT) market